[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342355-105":59,"doc-detail-342355-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","inclusion-of-surgery-in-multimodality-treatment-is-predictive-of-better-survival-in-stage-iiia-non-small-cell-lung-cancer-an-inverse-probability-treatment-weighting-analysis","Inclusion of Surgery in Multimodality Treatment is Predictive of Better Survival in Stage IIIA Non-small Cell Lung Cancer - An Inverse Probability Treatment-Weighting Analysis","","Stage IIIA non-small cell lung cancer (NSCLC) is managed with either surgery-based multimodality therapy or definitive chemoradiation followed by durvalumab consolidation, but the survival benefit of surgery-based strategies over immunotherapy consolidation remains unclear. Using the National Cancer Database, survival between treatment groups was compared with inverse probability treatment weighting (IPTW)-adjusted Kaplan–Meier curves and Cox models, with Landmark Inverse and Clone Censor Weight analyses to address immortal time bias.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/inclusion-of-surgery-in-multimodality-treatment-is-predictive-of-better-survival-in-stage-iiia-non-small-cell-lung-cancer-an-inverse-probability-treatment-weighting-analysis/342355/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/inclusion-of-surgery-in-multimodality-treatment-is-predictive-of-better-survival-in-stage-iiia-non-small-cell-lung-cancer-an-inverse-probability-treatment-weighting-analysis/342355.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical treatments were compared for stage IIIA NSCLC in this study?","Question",{"text":112,"@type":113},"The study compared surgery-based multimodality therapy versus definitive chemoradiation with durvalumab consolidation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers compare survival between the two treatment groups?",{"text":117,"@type":113},"Survival differences were analyzed using IPTW-adjusted Kaplan–Meier curves and Cox proportional hazards regression.",{"name":119,"@type":110,"acceptedAnswer":120},"How was immortal time bias addressed?",{"text":121,"@type":113},"Findings were independently confirmed with Landmark Inverse and Clone Censor Weight analyses designed to mitigate immortal time bias.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342355,1790539252,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Clin Lung Cancer. Author manuscript; available in PMC 2025 September 18. |\n| --- | --- |\n\nPublished in final edited form as:  \nClin Lung Cancer. 2025 January ; 26(1): e81–e90. doi:10.1016/j.cllc.2024.10.007 .  \nInclusion of Surgery in Multimodality Treatment is Predictive of Better Survival in Stage IIIA Non-small Cell Lung Cancer: An Inverse Probability Treatment-Weighting Analysis  \nFeitong Lei 1,3 , Janeesh Sekkath-Veedu2 , Bin Huang 1,3 , Quan Chen3 , Mansi Shah-Jadeja4 , Thomas E. Stinchcombe5 , Zhonglin Hao2  \n1 Division of Cancer Biostatistics, Biostatistics and Bioinformatics Shared Resource Facility, Department of Medicine, Markey Comprehensive Cancer Center, University of Kentucky, Lexington, 40536 KY, USA  \n2 Department of Medicine, Markey Comprehensive Cancer Center, University of Kentucky, Lexington, 40536 KY, USA  \n3Biostatistics and Bioinformatics Shared Resource Facility, Markey Comprehensive Cancer Center, University of Kentucky, Lexington, 40536 KY, USA  \n4 Department of Cardiothoracic Surgery, Markey Comprehensive Cancer Center, University of Kentucky, Lexington, 40536 KY, USA  \n5 Duke Cancer Institute, Duke University School of Medicine, Durham, 27710 NC, USA  \nAbstract  \nIntroduction: Stage IIIA non-small cell lung cancers (NSCLC) are treated with surgery-based multimodality approach or definitive chemoradiation therapy plus durvalumab consolidation. It isnot clear whether surgery-based multimodality therapy has any survival advantage over definitive chemoradiation plus immunotherapy consolidation.  \nMethod: National Cancer Database (NCDB) was used to identify NSCLC patients at stage IIIA (AJCC8, T3N1/T4N0–1 or T1N2/T2N2) who are treated with surgery-based multimodality approach or definitive chemoradiation plus durvalumab. Survival between groups were compared using inverse probability treatment weighting (IPTW)-adjusted Kaplan Meier curves and Cox proportional hazards regression analysis. Results were independently confirmed by Landmark Inverse and Clone Censor Weight analyses to address immortal time bias.  \nThis is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/))  \nAddress for correspondence: Zhonglin Hao, MD, PhD, Department of Medicine, Markey Comprehensive Cancer Center, University of Kentucky, Lexington, KY 40513, [USA. Zhonglin.hao@uky.edu](USA. Zhonglin.hao@uky.edu).  \nCRediT authorship contribution statement  \nFeitong Lei: Writing – review & editing, Writing – original draft, Validation, Software, Methodology, Formal analysis, Data curation. Janeesh Sekkath-Veedu: Investigation, Formal analysis, Data curation, Conceptualization. Bin Huang: Supervision, Software, Investigation, Formal analysis, Data curation. Quan Chen: Methodology, Formal analysis, Data curation. Mansi Shah-Jadeja:  \nInvestigation, Conceptualization. Thomas E. Stinchcombe: Writing – review & editing, Writing – original draft. Zhonglin Hao: Writing – review & editing, Writing – original draft, Supervision, Methodology, Investigation, Formal analysis, Data curation, Conceptualization.  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nLei et al. Page 2  \nResults: From 2017 to 2019, 24,170 patients are identified as potentially resectable stage  \nIIIA (T3N1, T4N0–1, T1N2/T2N2). Among them, 2,615 (10.8%) received surgery-based multimodality therapy and 2,985 (12.4%) received definitive chemoradiation plus durvalumab.  \nSurgery based multimodality approach had significant survival advantage over definitive chemoradiation plus durvalumab (HR 0.74; 95% CI 0.69–0.79, P \u003C .001) . The median overall survival (mOS) for the definitive chemoradiation plus durvalumab group was 48.59 m whereas mOS was not reached for surgery-based multimodality group. This trend persisted in both N2 negative a","cbCaiebNUbbNO7LJ","https://ap.wps.com/l/cbCaiebNUbbNO7LJ","pdf",1063140,17,"English","# Introduction\n## Study question and clinical background\n# Methods\n## Patient selection from NCDB\n## IPTW-adjusted survival analyses\n## Immortal time bias sensitivity analyses\n# Results\n## Patient distribution and survival outcomes\n## Subgroup persistence and therapy timing\n# Conclusion\n## Comparative survival findings for stage IIIA NSCLC","[{\"question\":\"What clinical treatments were compared for stage IIIA NSCLC in this study?\",\"answer\":\"The study compared surgery-based multimodality therapy versus definitive chemoradiation with durvalumab consolidation.\"},{\"question\":\"How did the researchers compare survival between the two treatment groups?\",\"answer\":\"Survival differences were analyzed using IPTW-adjusted Kaplan–Meier curves and Cox proportional hazards regression.\"},{\"question\":\"How was immortal time bias addressed?\",\"answer\":\"Findings were independently confirmed with Landmark Inverse and Clone Censor Weight analyses designed to mitigate immortal time bias.\"}]","Inclusion of Surgery in Multimodality Treatment is Predictive of Better Survival in Stage IIIA Non-small Cell Lung Cancer - An Inverse Probability Treatment-Weighting Analysis | PDF",1790046263,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9ad52e6e5dc822167197fdb926d61e8.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0ad8542c1437f87b6484857886baa0b.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28f736a29cf4f247c0e14501a9e32f63.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ddfa3ff9245133582ee03ea36b8abac9.webp",980,1268]